Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Why Cytosolic crRNAs Improve Cas13 RNA Control
2026-11-18
A mechanistic editorial on how U1-driven CRISPR RNAs alter intracellular guide localization and improve Cas13-based RNA knockdown, editing, translational repression and miRNA-related regulation, while distinguishing direct evidence from plausible explanations and broader applicability.
How Virginiamycin S1 Blocks Bacterial Translation
2026-11-18
A mechanistic guide to interpreting Virginiamycin S1: how ribosomal binding can produce translation arrest, why MRSA susceptibility readouts require context, and how streptogramin synergy and cfr-associated resistance shape conclusions.
How Should N6-Methyladenosine Findings Be Read?
2026-11-17
N6-methyladenosine can describe both a free modified nucleoside and the covalent m6A RNA modification. Separating biochemical, RNA-level and cellular readouts clarifies what the documented cAMP, mRNA and erythroleukemia findings support—and what they do not yet connect causally.
How AKT2 Inhibition Connects to Cellular Readouts
2026-11-17
CCT128930 HCl is described as an ATP-competitive AKT2 inhibitor whose biochemical selectivity, pathway biomarkers, cell-cycle effects, and tumor-model observations form a linked but not interchangeable evidence chain. The key interpretation question is how confidently a molecular interaction can be connected to downstream signaling and antiproliferative phenotypes.
How GSK690693 Links Akt Binding to Cell Readouts
2026-11-16
GSK690693 is documented as a reversible ATP-competitive inhibitor of Akt1, Akt2, and Akt3, with additional activity across several kinases. Its reported effects illustrate how biochemical target engagement can connect to phosphorylation changes, cellular phenotypes, and tumor-model outcomes—while also showing why those readouts cannot be treated as interchangeable measures of Akt selectivity or clinical efficacy.
Cy3 Maleimide and the H1 Repair Evidence
2026-11-16
Published comparisons support a phosphorylation-sensitive role for linker histone H1 in replication-stress repair, but they do not yet establish a fully quantitative or phosphorylation-specific mechanism. Cy3 maleimide is best understood as a thiol-reactive fluorescence reagent in the measurement layer, not as the cause of the reported repair phenotype.
How UK-5099 Links Pyruvate to Energy Readouts
2026-11-15
UK-5099, also known as PF-1005023, is described as a mitochondrial pyruvate carrier inhibitor whose effects connect pyruvate transport with respiration, cellular energy state, and whole-body glucose handling. The documented results support a mechanistic interpretation, while the different assay levels should not be treated as interchangeable evidence of insulin secretion or clinical efficacy.
Interpreting GSK690693 Across Evidence Levels
2026-11-14
How should GSK690693 findings be interpreted from kinase binding through cellular and tumor-model outcomes? The documented evidence supports a mechanistic chain involving ATP-site competition, reduced Akt signaling, altered tumor-cell survival, and activity in several preclinical models, while its kinase cross-reactivity limits strictly Akt-specific conclusions.
How to Interpret Glycyrrhetinic Acid Claims
2026-11-13
Glycyrrhetinic acid is documented as a glycyrrhizic acid derivative with broad associations in inflammation, liver, viral, cancer-biology, and metabolic research. The useful interpretive distinction is between chemical identity, physicochemical behavior, molecular mechanism, cellular readouts, and organism-level benefit.
How PTEN Inhibition Shapes Neutrophil Signaling
2026-11-13
SF1670 is described as an active-site PTEN inhibitor that increases PtdIns(3,4,5)P3-dependent signaling in neutrophils. The documented findings connect molecular inhibition with Akt phosphorylation, reactive oxygen species production, cell polarization, bacterial killing, and reduced lung injury in a mouse pneumonia model, while leaving important questions about quantitative efficacy and broader applicability.
How Lubabegron Could Affect Ammonia Emissions
2026-11-12
Lubabegron is documented as a beta-adrenergic receptor modulator with mixed agonist and antagonist activity in cattle, alongside a reported reduction in ammonia-related emissions from animals or their wastes. The scientifically important question is how a receptor-level effect could influence nitrogen excretion and subsequent gas release. The available documentation supports a plausible mechanistic framework, but not independent causal proof or a quantified estimate of emission reduction.
How Should BT2’s BCKDC IC50 Be Read?
2026-11-12
BT2, or 3,6-dichlorobenzo[b]thiophene-2-carboxylic acid, is documented as a selective inhibitor of BCKDC kinase. Its reported 3.19 μM IC50 supports inhibition in a biochemical assay, while the proposed conformational mechanism explains how kinase activity may be reduced. Neither finding alone establishes altered branched-chain amino acid catabolism in cells or organisms.
What Super-Resolution Proximity Actually Measures
2026-11-11
Super-resolution microscopy can improve the spatial description of organelles, but a measured juxtapositional signal is not equivalent to a molecularly verified contact site. The evidence supports a careful separation between fluorescent labeling, image reconstruction, segmentation accuracy, and biological interpretation.
What SGK1 Potency Means Across Assays
2026-11-11
A comparison of biochemical and cellular findings shows why an inhibitor’s apparent potency changes across assay systems, and how SGK1 inhibition may connect to androgen-responsive prostate cancer cell growth.
How Hsp90 Inhibition May Disrupt Myeloma Signaling
2026-11-10
KW-2478 is described as a nonansamycin Hsp90 inhibitor whose documented effects in multiple myeloma cells connect client-protein loss with changes in transcriptional and translational control. The evidence supports a mechanistic interpretation, while the absence of independent quantitative study details limits conclusions about selectivity, comparative potency, and clinical relevance.